Skip to search formSkip to main contentSkip to account menu

ICRF-159

Known as: ICI 59118, ICRF 159, ICRF159 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

razoxane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1998
Review
1998
Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs.
Highly Cited
1995
Highly Cited
1995
DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Bisdioxopiperazines such as ICRF-159 and ICRF-193 have been shown to inhibit DNA topoisomerase II. To determine the molecular… 
Highly Cited
1991
Highly Cited
1991
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Several recently developed derivatives of bis(2,6-dioxopiperazine) have been shown to be new antitumor agents and are currently… 
1989
1989
Isoproterenol-induced cytotoxicity in neonatal rat heart cell cultures is mediated by free radical formation.
1983
1983
Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159.
Cardiotoxicity of doxorubicin, 2 mg/kg i.p. twice weekly in rats, was assessed by serial electrocardiography and electron… 
Highly Cited
1980
Highly Cited
1980
Razoxane (ICRF 159) in the treatment of psoriasis
This paper describes our experience with the use of razoxane (ICRF 159), a new anti‐mitotic drug, in the treatment of thirty‐six… 
1977
1977
Study of trans-cyclopropylbis (diketopiperazine) and chelating agents related to ICRF 159. Cytotoxicity, mutagenicity, and effects on scheduled and unscheduled DNA synthesis.
The cytotoxicity, mutagenicity, and DNA damaging potential of trans-cyclopropylbis (diketopiperazine) (3) and chelating agents… 
1975
1975
The bioavailability in man of ICRF‐159 a new oral antineoplastic agent
The bioavailability of the antineoplastic agent, ICRF‐159, has been examined in 12 patients receiving the drug in single and… 
1974
1974
Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors
ICRF 159, an antimitotic agent that increases the antitumor activity of most antineoplastic drugs, has now also been shown to… 
1974
1974
Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159
In a pilot clinical assessment of combined radiotherapy with the antimitotic agent ICRF 159, a good response was obtained in 18… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)